Philip Morris International
PM
$194.30
+3.33%
Philip Morris International Inc. (PM) is a global tobacco company that sells cigarettes and reduced-risk products, including heated tobacco, vapes, and oral nicotine offerings, primarily outside the United States. It is a market leader in the tobacco industry, with dominant positions in heated tobacco through its IQOS brand and in nicotine pouches through Zyn, following the 2023 acquisition of Swedish Match. The current investor narrative centers on PM's transformation toward a smoke-free future, with strong growth in reduced-risk products driving revenue acceleration, while regulatory risks and declining cigarette volumes remain key debates.…
PM
Philip Morris International
$194.30
Related headlines
Investment Opinion: Should I buy PM Today?
Rating: Buy. PM offers a compelling risk/reward with accelerating RRP growth, expanding margins, and a low PEG ratio, supported by a consensus Buy rating (mean 1.8) and average target of $194.86. The thesis hinges on successful smoke-free transformation driving sustained revenue growth above 8% and margin expansion.
Supporting evidence: (1) Revenue growth accelerated to 9.09% YoY in Q1 2026, with RRPs at 43.2% of sales. (2) Net margin improved to 24.03% from 20.66% in Q4 2025. (3) TTM FCF of $10.666B supports a 3.45% dividend yield and buybacks. (4) PEG ratio of 0.36x indicates undervaluation relative to growth, while trailing P/E of 22.06x is near historical mid-range. The stock is fairly valued relative to history but undervalued on a growth-adjusted basis.
Risks & Conditions: Key risks include regulatory setbacks for RRPs, negative equity from buybacks, and limited near-term upside to analyst targets. This Buy rating would downgrade to Hold if revenue growth decelerates below 7% or if net margin falls below 22%. Upgrade to Strong Buy if PEG remains below 0.5x and RRP revenue share exceeds 50%. Overall, PM is fairly valued relative to history but undervalued on a growth-adjusted basis, making it a Buy for long-term investors.
Sign up to view all
PM 12-Month Price Forecast
PM's outlook is bullish given the accelerating revenue growth from reduced-risk products, expanding margins, and attractive PEG ratio. The base case of 55% probability assumes continued RRP momentum driving 7-9% total revenue growth, supporting the stock near the average target. Upside catalysts include new market launches and favorable regulation, while downside risks center on regulatory headwinds. The medium confidence reflects the stock's proximity to its 52-week high and limited near-term upside to analyst targets. A stance upgrade to high confidence would require sustained revenue growth above 10% and clear regulatory progress.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Philip Morris International's 12-month outlook, with a consensus price target around $196.27 and implied upside of +1.0% versus the current price.
Average Target
$196.27
0 analysts
Implied Upside
+1.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$171 - $216
Analyst target range
PM is covered by 14 analysts, with a consensus recommendation of 'Buy' (mean recommendation 1.8 on a 1-5 scale, where 1 is Strong Buy). The average target price is $194.86, implying a modest +0.97% upside from the current price of $192.98. The distribution shows 10 Buy ratings, 3 Hold, and 1 Sell, indicating a generally bullish sentiment. The target price range spans from a low of $171.00 to a high of $210.00. The high target of $210.00 assumes continued strong growth in reduced-risk products and potential multiple expansion, while the low target of $171.00 prices in risks such as regulatory headwinds or slower adoption of smoke-free products. Recent ratings actions show stability, with UBS maintaining Neutral, Morgan Stanley reiterating Overweight, and Needham and Stifel maintaining Buy. The spread between low and high targets ($39) is moderate, reflecting reasonable uncertainty but not extreme divergence in analyst views.
Bulls vs Bears: PM Investment Factors
PM presents a compelling bull case driven by accelerating revenue growth from reduced-risk products (9.09% YoY), expanding margins (net margin 24.03%), and strong cash flow generation ($10.666B TTM). The PEG ratio of 0.36x suggests undervaluation relative to growth, while low beta (0.405) offers defensive appeal. However, bear points include limited analyst upside (+0.97% to average target), negative equity from buybacks, and regulatory risks that could hinder RRP adoption. The central tension is whether PM's smoke-free transformation can sustain double-digit revenue growth and margin expansion, justifying a premium valuation, or if regulatory headwinds and cigarette decline will cap returns. Currently, the bull case has stronger evidence given the accelerating growth trajectory and attractive PEG ratio, but the stock's proximity to its 52-week high limits near-term upside.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 9.09% YoY to $10.146B, up from 7.71% YoY in Q1 2025, driven by reduced-risk products (RRPs) which now contribute 43.2% of total revenue. This accelerating top-line momentum signals successful portfolio transformation.
- Expanding Profit Margins: Net margin improved to 24.03% in Q1 2026 from 20.66% in Q4 2025, and operating margin rose to 38.37% from 32.55% over the same period. This demonstrates operational leverage and cost discipline.
- Strong Free Cash Flow Generation: TTM free cash flow stands at $10.666B, providing ample capacity for debt service (interest coverage ratio 16.43x), dividends (3.45% yield), and share buybacks. The payout ratio of 76% is sustainable given cash flow strength.
- Attractive Valuation with PEG Ratio: With a trailing P/E of 22.06x and a PEG ratio of 0.36x, the stock appears undervalued relative to its earnings growth rate. The forward P/E of 21.11x implies modest growth expectations, leaving room for upside if growth accelerates.
Bearish
- Declining Cigarette Volumes: Combustible products still represent 56.8% of revenue, and global cigarette volumes are in secular decline. Regulatory pressures and health trends could accelerate volume erosion, pressuring legacy revenue.
- Negative Equity from Buybacks: Debt-to-equity ratio of -4.89 reflects negative shareholders' equity due to aggressive share repurchases. While cash flow covers debt, negative equity increases financial risk if earnings decline.
- Modest Analyst Upside: The average analyst target of $194.86 implies only +0.97% upside from the current price of $192.98. With the stock near its 52-week high, limited near-term appreciation potential exists.
- Regulatory and Litigation Risks: PM faces ongoing regulatory scrutiny in key markets (EU, Asia) regarding heated tobacco and nicotine pouch marketing. Adverse rulings could restrict RRP growth or impose additional taxes, impacting margins.
PM Technical Analysis
PM is in a sustained uptrend, with a 1-year price change of +7.71% and the stock trading at $192.98, near the top of its 52-week range (52-week high: $194.58, low: $142.11). The current price is at 99.2% of the 52-week high, indicating strong momentum and bullish sentiment, though it also suggests the stock may be overextended in the near term. Short-term momentum is accelerating, with a 1-month change of +7.55% and a 3-month change of +22.30%, significantly outperforming the S&P 500's 1-month and 3-month returns of +0.31% and +4.67%, respectively. The relative strength index is not provided, but the strong price action and volume of 5.2 million shares suggest robust buying interest. The 52-week low of $142.11 serves as key support, while the 52-week high of $194.58 is immediate resistance. A breakout above $194.58 could signal further upside, while a breakdown below $142.11 would indicate a bearish reversal. With a beta of 0.405, PM is significantly less volatile than the market, making it a lower-risk holding suitable for conservative portfolios.
Beta
0.41
0.41x market volatility
Max Drawdown
-22.0%
Largest decline past year
52-Week Range
$142-$200
Price range past year
Annual Return
+17.6%
Cumulative gain past year
| Period | PM Return | S&P 500 |
|---|---|---|
| 1m | +12.2% | +0.4% |
| 3m | +14.8% | +5.5% |
| 6m | +12.3% | +8.4% |
| 1y | +17.6% | +18.9% |
| ytd | +21.2% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PM Fundamental Analysis
PM's revenue trajectory is accelerating, with Q1 2026 revenue of $10.146 billion, up 9.09% year-over-year, compared to Q1 2025 revenue of $9.301 billion. The multi-quarter trend shows consistent growth, with Q4 2025 revenue of $10.362 billion and Q3 2025 revenue of $10.845 billion. Revenue segments reveal that Reduced-Risk Products contributed $4.379 billion (43.2% of total), while Combustible Products contributed $5.767 billion, highlighting the shift toward smoke-free products as a key growth driver. The company is highly profitable, with Q1 2026 net income of $2.438 billion and a gross margin of 68.06%. Net margin improved to 24.03% in Q1 2026 from 20.66% in Q4 2025, indicating expanding profitability. Operating margin also rose to 38.37% from 32.55% over the same period, reflecting operational efficiency. PM has a strong balance sheet with free cash flow (TTM) of $10.666 billion, though Q1 2026 free cash flow was negative -$752 million due to working capital changes. The debt-to-equity ratio is -4.89 (negative equity due to large share buybacks), but the company generates ample cash to service debt, with an interest coverage ratio of 16.43x. ROE is negative (-1.14) due to negative equity, but return on assets (ROA) of 15.46% indicates efficient asset utilization.
Quarterly Revenue
$10.1B
2026-03
Revenue YoY Growth
+9.1%
YoY Comparison
Gross Margin
68.1%
Latest Quarter
Free Cash Flow
$10.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PM Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. PM's trailing P/E is 22.06x, while the forward P/E is 21.11x, implying the market expects modest earnings growth. The gap between trailing and forward P/E suggests a slight de-risking of growth expectations. Compared to the industry average (not provided), PM's P/E of 22.06x appears reasonable for a dominant player with strong margins and growth in reduced-risk products. The PEG ratio of 0.36x indicates the stock is undervalued relative to its earnings growth rate, assuming the growth estimates are accurate. Historically, PM's trailing P/E has ranged from 15.3x (Q3 2022) to 29.3x (Q4 2025). The current 22.06x is near the middle of this range, suggesting the stock is fairly valued relative to its own history. The P/S ratio of 6.14x is below the historical high of 27.97x (Q2 2025), indicating that revenue multiples have compressed, possibly due to market concerns about cigarette volume declines.
PE
22.1x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: PM's negative equity (-4.89 debt-to-equity) from aggressive buybacks creates a fragile balance sheet, though interest coverage of 16.43x and TTM FCF of $10.666B provide a cushion. The Q1 2026 negative FCF of -$752M highlights working capital volatility. Net margin improvement to 24.03% is positive, but any reversal could pressure earnings. Revenue concentration in combustible products (56.8%) remains a risk as cigarette volumes decline secularly.
Market & Competitive Risks: The stock trades near its 52-week high ($192.98 vs $194.58), limiting upside to the average analyst target of $194.86 (+0.97%). With a beta of 0.405, PM is less sensitive to macro swings, but regulatory actions (e.g., flavor bans, tax increases) in key markets like the EU could disrupt RRP growth. Competition from other tobacco companies and alternative nicotine products (e.g., vapes) could slow market share gains.
Worst-Case Scenario: A severe regulatory crackdown on heated tobacco and nicotine pouches, combined with faster-than-expected cigarette volume decline, could drive revenue growth below 5% and compress margins. In this scenario, the stock could fall to the 52-week low of $142.11, representing a -26.4% decline from the current price of $192.98. Analyst low target of $171.00 implies a -11.4% downside, but a broader market selloff could exacerbate losses.
FAQ
The key risks are: (1) Regulatory risk: Adverse rulings on heated tobacco or nicotine pouches in the EU or Asia could slow RRP growth, which is critical for the bull case. (2) Financial risk: Negative equity (-4.89 debt-to-equity) from buybacks creates balance sheet fragility, though interest coverage of 16.43x mitigates near-term concerns. (3) Competitive risk: Other tobacco companies and alternative nicotine products (vapes, oral nicotine) could erode market share. (4) Volume decline: Combustible products still represent 56.8% of revenue, and accelerating cigarette volume declines could pressure legacy earnings. The most severe risk is a regulatory crackdown that could reduce the stock to the 52-week low of $142.11 (-26.4% from current price).
The 12-month forecast is moderately bullish with a base case target of $185-195 (55% probability), assuming continued RRP growth of 10-12% and stable margins. The bull case (25% probability) targets $195-210, driven by strong IQOS/Zyn adoption and multiple expansion. The bear case (20% probability) targets $171-185, reflecting regulatory headwinds and slower growth. The most likely scenario is the base case, where the stock trades near the analyst average target of $194.86, offering modest upside. Key assumptions include sustained RRP momentum and no major regulatory disruptions. The AI assessment is bullish with medium confidence, citing the attractive PEG ratio and accelerating growth.
PM is fairly valued relative to its own history but undervalued on a growth-adjusted basis. The trailing P/E of 22.06x is near the middle of its 5-year range (15.3x to 29.3x), suggesting fair valuation. However, the PEG ratio of 0.36x indicates the stock is cheap relative to its earnings growth rate, implying the market is not fully pricing in the potential of reduced-risk products. The forward P/E of 21.11x is slightly below the trailing multiple, reflecting modest growth expectations. Compared to the broader market, PM's P/E is in line with the S&P 500, but its low beta and defensive nature warrant a premium. Overall, the stock is attractively valued for a company with accelerating growth and strong cash flows.
PM is a good buy for long-term investors seeking a defensive growth stock with a 3.45% dividend yield. The company's accelerating revenue growth (9.09% YoY in Q1 2026) driven by reduced-risk products (43.2% of revenue) and expanding margins (net margin 24.03%) support a Buy rating. The PEG ratio of 0.36x suggests the stock is undervalued relative to its earnings growth rate, while the consensus analyst target of $194.86 implies modest upside. However, the stock trades near its 52-week high, limiting near-term appreciation. The biggest downside risk is regulatory action against heated tobacco or nicotine pouches, which could slow RRP growth. For risk-averse investors with a 3-5 year horizon, PM offers a compelling risk/reward.
PM is best suited for long-term investment (3-5 years) due to its defensive characteristics (beta 0.405), growing dividend (3.45% yield), and structural growth story in reduced-risk products. Short-term trading is less attractive given the stock's proximity to its 52-week high and limited upside to the average analyst target (+0.97%). The low volatility and steady earnings growth make it a core holding for conservative portfolios. A minimum holding period of 3 years is recommended to capture the full benefit of the smoke-free transformation and dividend compounding. Short-term catalysts like earnings beats could provide trading opportunities, but the stock's low beta limits rapid gains.